Cell and gene therapy in Australia

References

• Macpherson JL, Boyd MP, Ely JA, et al. Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients. J Gene Med 2005; 7: 552–64
   PubMed Web of Science ®Google Scholar
• Amado RG, Ronald T, Mitsuyasu RT, et al. Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther 2004; 15: 251–62
   PubMed Web of Science ®Google Scholar
• Ginn SL, Curtin JA, Kramer B, et al. Treatment of an infant with X-linked severe combined immunodeficiency (SCID-X1) by gene therapy in Australia. Med J Australia 2005; 182: 458–63
   PubMed Web of Science ®Google Scholar
• Chng K, Larsen SR, Zhou S, et al. Specific adeno-associated virus serotypes facilitate efficient gene transfer into human and non-human primate mesenchymal stromal cells. J Gene Med 2007; 9: 22–32
   Google Scholar
• Ellem KA, O'Rourke MG, Johnson GR, et al. A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997; 44: 10–20
   PubMed Web of Science ®Google Scholar
• O'Rourke MGE, Johnson M, Davern D, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003; 52: 387–95
   PubMed Web of Science ®Google Scholar
• Teng MWL, Kershaw MH, Moeller M, et al. Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Human Gene Ther 2004; 15: 699–708
   PubMed Web of Science ®Google Scholar
• Teng MWL, Kershaw MH, Jackson JT, et al. Adoptive transfer of chimeric Fc epsilon RI receptor gene-modified human T cells for cancer immunotherapy. Human Gene Ther 2006; 17: 1134–43
   PubMedGoogle Scholar
• Royal RE, Kershaw MH, Reeves ME, et al. Increased functional expression of transgene in primary human lymphocytes using retroviral vectors modified with IRES and splicing motifs. Gene Ther 2002; 9: 1085–92
   Google Scholar
• Parker LL, Do MT, Westwood JA, et al. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 2000; 11: 2377–87
   PubMed Web of Science ®Google Scholar
• Westwood JA, Smyth MJ, Teng MW, et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA 2005; 102: 19051–6
   PubMed Web of Science ®Google Scholar
• Yang S, An X, Brown RD , et al. Development of retargeted CD38-specific NK-92 cell line for potential anti-myeloma therapy. Abstracts for the 47th Annual Meeting of the American Society of Hematology. Blood 2005;106(abstr 5104):358b.
   Google Scholar
• Kovacic JC, Graham RM. Stem-cell therapy for myocardial diseases. Lancet 2004; 363: 1735–6
   Google Scholar
• Kovacic JC, Graham RM. Are improvements in cardiac function due to stem cell uptake and engraftment?. Am J Cardiol 2005; 95: 59
   Google Scholar
• Kovacic JC, Muller DWM, Harvey R, Graham RM. An update on the use of stem cells for cardiac disease. Intern Med J 2005; 35: 348–56
   Google Scholar
• Kovacic JC, Muller DWM, Graham RM. Actions and therapeutic potential of G-CSF and GM-CSF in cardiovascular disease. J Mol Cell Cardiol 2007; 42: 19–33
   PubMed Web of Science ®Google Scholar
• Kovacic JC, Macdonald P, Freund J, et al. Profound thrombocytopenia related to G-CSF. Am J Hematol 2007; 82: 229–30
   Google Scholar
• Boyle A, Whitbourn R, Schlicht S, et al. Intra-coronary high-dose CD34+ stem cells in patients with chronic ischemic heart disease: a 12-month follow-up. Int J Cardiol 2006; 109: 21–7
   PubMed Web of Science ®Google Scholar
• Féron F, Perry C, Cochrane J, et al. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain 2005; 128: 2951–60
   PubMed Web of Science ®Google Scholar
• Prince HM, Simmons PJ, Whitty G, et al. Improved hemopoietic recovery following transplantation with ex vivo expanded mobilized blood cells. Brit J Hematol 2004; 126: 536–45
   PubMed Web of Science ®Google Scholar
• Ho S-J, Dyson P, Rawling T , et al. Mesenchymal stem cells for the treatment of steroid-resistant graft-versus-host-disease. HSANZ, ANZSBT, ASTH Annual Scientific Meeting, Wrest Point Conference Centre, Hobart Tasmania. 2006:(A120): 184.
   Google Scholar
• Dean SK, Yulyana Y, Williams G, et al. Differentiation of encapsulated embryonic stem cells after transplantation. Transplantation 2006; 82: 1175–84
   PubMedGoogle Scholar
• Brisby H, Tao H, Ma DD, et al. Cell therapy for disc degeneration-potentials and pitfalls. Orthop Clin North Am 2004; 35: 85–93
   Google Scholar
• Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390–7
   PubMed Web of Science ®Google Scholar
• Smythe G, Lai MC, Grounds MD, Rakoczy PE. Adeno-associated virus-mediated vascular endothelial growth factor gene therapy in skeletal muscle before transplantation promotes revascularization of regenerating muscle. Tissue Eng 2002; 8: 879–91
   Google Scholar